Swiss pharmaceutical giant Roche announced on Thursday that its first-quarter sales increased by 7%, reaching 15.44 billion Swiss francs ($18.64 billion). The company also confirmed its guidance for the full year, signaling confidence in continued performance amid global healthcare sector shifts.
The sales growth was broadly in line with market expectations and reflects steady demand across Roche’s portfolio of diagnostics and innovative medicines. While the company didn’t provide a detailed breakdown of revenue by division in the brief earnings note, analysts anticipate further insights in the full earnings call scheduled later this month.
CEO Thomas Schinecker had previously expressed optimism for 2025, noting that new drug launches and expanded use of existing therapies—particularly in oncology and rare diseases—are expected to drive growth.
Roche’s reaffirmation of its 2025 outlook provides reassurance to investors amid a volatile earnings season across global healthcare and biotech sectors. The company maintained its forecast of low- to mid-single-digit sales growth for the year at constant exchange rates.
The stock, traded under the ticker ROG.SW, edged up 1.3% in early European trading following the announcement.
